Compare

HGH (Somatropin) vs MK-677

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

HGH (Somatropin)

89 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 53% · Mixed 34% · Unfavorable overall 13%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
24
Digestive comfort
126
Skin appearance
71
Appetite control
86
Energy
178

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
120
Flushing
25
Headache
36
GI discomfort
82
Dizziness
178

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–3 mg

0.01–0.025 mg
4
0.025–0.05 mg
11
0.05–0.1 mg
14
0.1–0.2 mg
19
0.2–0.4 mg
29
0.4–0.6 mg
24
0.6–1 mg
13
1–2 mg
4
2–3 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing13stacking36side effects19hgh (somatropin)22

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 19 days · Based on 20 repeat reporters

MK-677

503 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
-122
Digestive comfort
-163
Skin appearance
-123
Appetite control
-140
Energy
-97

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Anxiety
-26
Flushing
-83
Headache
-158
GI discomfort
-145
Dizziness
-98

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.2–5 mg

0.2–0.4 mg
10
0.4–0.6 mg
12
0.6–1 mg
17
1–2 mg
9
2–3 mg
10
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking20side effects13mk-67711

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 31 days · Based on 111 repeat reporters

Sources (8)

Published sources linked on the HGH (Somatropin) and MK-677 wiki pages.

  1. PubMed

    Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline

    Molitch ME, Clemmons DR, Malozowski S, et al. J Clin Endocrinol Metab. 2011

    Source
    Wiki study page →
  2. PubMed

    Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis

    Mameli C, Orso M, Calcaterra V, et al. Pharmacological research. 2023

    Source
    Wiki study page →
  3. PubMed

    MK-677, an orally active growth hormone secretagogue: effects on body composition

    Murphy MG, Plunkett LM, Gertz BJ, et al. J Clin Endocrinol Metab. 1998

    Source
    Wiki study page →
  4. PubMed

    Two-year treatment with ibutamoren increases bone mineral density, body composition, and quality of life

    Nass R, Pezzoli SS, Oliveri MC, et al. J Clin Endocrinol Metab. 2008

    Source
    Wiki study page →
  5. ClinicalTrials.gov

    Ibutamoren (MK-677) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  6. PubMed

    MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism

    Murphy MG, Plunkett LM, Gertz BJ, et al. The Journal of clinical endocrinology and metabolism. 1998

    Source
    Wiki study page →
  7. PubMed

    Characterization of growth hormone secretagogue small molecule ibutamoren (MK-0677) and its possible metabolites in thoroughbred horses for doping control

    Philip M, Karakka Kal AK, Subhahar MB, et al. Rapid communications in mass spectrometry : RCM. 2022

    Source
    Wiki study page →